Brokerages Set Organon & Co. (NYSE:OGN) PT at $19.75

Shares of Organon & Co. (NYSE:OGN - Get Free Report) have been given a consensus rating of "Hold" by the four brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $19.67.

A number of brokerages have issued reports on OGN. Morgan Stanley decreased their price target on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Evercore ISI downgraded shares of Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday. Barclays lowered their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th.

Organon & Co. Trading Up 1.6 %

NYSE:OGN traded up $0.15 on Wednesday, reaching $9.60. The stock had a trading volume of 13,582,579 shares, compared to its average volume of 2,896,722. Organon & Co. has a 12-month low of $9.18 and a 12-month high of $23.10. The company has a market cap of $2.50 billion, a price-to-earnings ratio of 2.88, a P/E/G ratio of 0.90 and a beta of 0.73. The firm's fifty day moving average is $13.46 and its two-hundred day moving average is $14.96. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. The firm had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Organon & Co.'s revenue was down 6.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.22 earnings per share. Equities analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Monday, May 12th will be given a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Monday, May 12th. Organon & Co.'s payout ratio is currently 33.63%.

Institutional Trading of Organon & Co.

Institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. boosted its position in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after buying an additional 11,140,388 shares during the period. Norges Bank acquired a new stake in Organon & Co. in the fourth quarter valued at approximately $25,258,000. Magnetar Financial LLC raised its stake in shares of Organon & Co. by 560.2% during the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company's stock valued at $25,878,000 after purchasing an additional 1,471,731 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Organon & Co. by 8.3% during the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock worth $159,553,000 after purchasing an additional 820,378 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Organon & Co. in the fourth quarter valued at $11,892,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.